Antiviral drug discovery targeting to viral proteases

Current Pharmaceutical Design

Volumn 12, Issue 11, 2006, Pages 1301-1314

  Hsu, John T A ^a,b   Wang, Hsiang Ching ^c   Chen, Guang Wu ^c   Shih, Shin Ru ^c,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Drug discovery; Viral protease

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ASPARTIC PROTEINASE; ATAZANAVIR; BENAZEPRIL; CAPTOPRIL; CILUPREVIR; CYSTEINE PROTEINASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENALAPRIL MALEATE; FOSINOPRIL; INDINAVIR; LISINOPRIL; LOPINAVIR PLUS RITONAVIR; METALLOPROTEINASE; MOEXIPRIL; NELFINAVIR; PERINDOPRIL; PROTEINASE; PROTEINASE INHIBITOR; QUINAPRIL; RAMIPRIL; RITONAVIR; RUPINTRIVIR; SAQUINAVIR; SERINE PROTEINASE; TRANDOLAPRIL; VIRUS DNA; VIRUS RNA; ANTIVIRUS AGENT;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; FLAVIVIRUS; GENE TARGETING; GENETIC ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; WEST NILE FLAVIVIRUS; ANTIBIOTIC RESISTANCE; CORONAVIRUS; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; PICORNAVIRUS;

ANTIVIRAL AGENTS; CORONAVIRUS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HERPESVIRIDAE; HIV PROTEASE INHIBITORS; PICORNAVIRIDAE; PROTEASE INHIBITORS;

EID: 33744988629     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361110     Document Type: Review

References (121)

1. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G., Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
2. Knipe D, Howley PM. Fields virology, 4th ed. Philadelphia, Lippincott Williams & Wilkins. 2001; 114-5.
3. Dougherty WG, Semler BL. Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev 1993: 57: 781-822.
4. De Francesco R, Steinkuhler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol 2000; 242: 149-69.
5. Mangel WF, Baniecki ML, McGrath WJ. Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid viral peptide, and the cellular protein actin. Cell Mol Life Sci 2003; 60: 2347-55.
6. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4: 544-58.
7. Tong L. Viral proteases. Chem Rev 2002; 102: 4609-26.
8. Gorbalenya AE, Donchenko AP, Blinov VM, Koonin EV. Cysteine proteases of positive strand RNA viruses and chymotrypin-like serine proteases. A distinct protein superfamily with a common structural fold. FEBS Lett 1989; 243: 103-14.
9. Malcolm BA. The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Protein Sci 1995; 4: 1439-45.
10. Qiu X, Culp JS, DiLella AG, Hellmig B, Hong SS, Janson CA, et al. Unique fold and active site in cytomegalovirus protease. Nature 1996; 383: 275-9.
11. Thiel V, Ivanov KA, Putics A, Hertzig T, Schelle B, Bayer S, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 2003, 84: 2305-15.
12. Ding J, McGrath WJ, Sweet RM, Mangel WF. Crystal structure of the human adenovirus proteinase with its 11 amino acid cofactor. EMBO J 1996, 15: 1778-83.
13. Pieroni L, Santolini E, Fipaldini C, Pacini L, Migliaccio G, La Monica N. In vitro study of the NS2-3 protease of hepatitis C virus. J Virol 1997: 71: 6373-80.
14. Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, et al. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol 2001; 75: 9939-46.
15. Billich A, Winkler G. Colorimetric assay of HIV-1 proteinase suitable for high-capacity screening. Pept Res 1990; 3: 274-6.
16. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 177: 1533-40.
17. Stebbins J, Debouck C. A microtiter colorimetric assay for the HIV-1 protease. Anal Biochem 1997; 248: 246-50.
18. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998, 55: 461-86.
19. Becker SL. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs 2003; 12: 401-12.
20. Lin JH, Ostovic D, Vacca JP. The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Pharm Biotechnol. 1998, 11: 233-55.
21. Vagelos R, Galambos L. Medicine, science, and merck. New York, Cambridge University Press. 2004; 272-4.
22. Werber Y. HIV drug market. Nat Rev Drug Discov 2003, 2: 513-4.
23. Vierling P, Greiner J. Prodrugs of HIV protease inhibitors. Curr Pharm Des 2003; 9: 1755-70.
24. Tavel JA. Ongoing trials in HIV protease inhibitors. Expert Opin Investig Drugs 2000; 9: 917-28.
25. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36: 1193-203.
26. Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother 2002, 3: 315-27.
27. Mangum EM, Graham KK. Lopinavir-Ritonavir: a new protease inhibitor. Pharmacotherapy 2001; 21: 1352-63.
28. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996; 271: 1582-6.
29. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
30. Ren S, Lien EJ. Development of HIV protease inhibitors: a survey. Prog Drug Res 1998; 51: 1-31.
31. Ryan MD, Flint M. Virus-encoded proteinases of the picornavirus super-group. J Gen Virol 1997; 78: 699-723.
32. Weidman MK, Sharm R, Raychaudhuri S, Kundu P, Tsai W, Dasgupta A. The interaction of cytoplasmic RNA viruses with the nucleus. Virus Res 2003; 95: 75-85.
33. pro has different domains for the RNA binding and proteolytic activities. J Biol Chem 1993; 268: 25735-9.
34. Walker PA, Leong LE, Porter AG. Sequence and structural determinants of the interaction between the 5′-noncoding region of picornavirus RNA and rhinovirus protease 3C. J Biol Chem 1995; 270: 14510-6.
35. Zell R, Sidigi K, Bucci E, Stelzner A, Gorlach M. Determinants of the recognition of enteroviral cloverleaf RNA by coxsackievirus B3 proteinase 3C. Rna 2002; 8: 188-201.
36. Shih SR, Chiang C, Chen TC, Wu CN, Hsu J T, Lee JC, et al. Mutations at KFRDI and VGK domains of enterovirus 71 3C protease affect its RNA binding and proteolytic activities. J Biomed Sci 2004; 11: 239-48.
37. Hayden FG., Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003, 47: 3907-16.
38. pro) structure: basis for design of anti-SARS drugs. Science 2003; 300: 1763-7.
39. Blom N, Hansen J, Blaas D, Brunak S. Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci 1996; 5: 2203-16.
40. Badorff C, Lee G.H, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, et al. Enteroviral protesse 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320-6.
41. Xiong D, Lee GFI, Badorff C, Dorner A, Lee S, Wolf P, et al. Dystrophin deficiency markedly increases enterovirus-induced cardio-myopathy: a genetic predisposition to viral heart disease. Nat Med 2002; 8: 872-7.
42. Lamphear BJ, Yan R, Yang F, Waters D, Liebig HD, Klump H, et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem 1993; 268: 19200-3.
43. Gradi A, Svitkin YV, Imataka H, Sonenberg N. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc Natl Acad Sci U S A 1998; 95: 11089-94.
44. Kerekatte V, Keiper BD, Badorff C, Cai A, Knowlton KU, Rhoads RE. Cleavage of Poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? J Virol 1999; 73: 709-17.
45. Seipelt J, Liebig HD, Sommergruber W, Gerner C, Kuechler E. 2A proteinase of human rhinovirus cleaves cytokeratin 8 in infected HeLa cells. J Biol Chem 2000; 275: 20084-9.
46. Kuyumcu-Martinez NM, Van Eden ME, Younan P, Lloyd RE. Cleavage of poly(A)-binding protein by poliovinis 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. Mol Cell Biol 2004; 24: 1779-90.
47. Kuyumcu-Martinez NM, Joachims M, Lloyd RE. Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. J Virol 2002, 76: 2062-74.
48. Anderson JF, Andreadis TG, Vossbrinck CR, Tirrell S, Wakem EM, French RA, et al. Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science 1999; 286: 2331-3.
49. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286: 2333-7.
50. Brinton MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 2002; 56: 371-402.
51. Nowak T, Farber PM, Wengler G. Analyses of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis. Virology 1989; 169: 365-76.
52. Arias CF, Preugschat F, Strauss JH. Dengue 2 vinis NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 1993; 193: 888-99.
53. Yamshchikov VF, Compans RW. Processing of the intracellular form of the west Nile virus capsid protein by the viral NS2B-NS3 protease: an in vitro study. J Virol 1994; 68: 5765-71.
54. Bazan JF, Fletterick RJ. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 1989: 171; 637-9.
55. Wengler G, Czaya G, Farber PM, Hegemann JH. In vitro synthesis of West Nile virus proteins indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids. J Gen Virol 1991; 72: 851-8.
56. Murthy HM, Clum S, Padmanabhan R. Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem 1999; 274: 5573-80.
57. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
58. Ryan MD, Monaghan S, Flint M. Virus-encoded proteinase of the Flaviviridae. J Gen Virol 1998; 79: 947-59.
59. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285: 110-3.
60. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-4.
61. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-90.
62. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 1437-49.
63. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001-14.
64. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300: 1145-8.
65. Colarusso S, Gerlach B, Koch U, Muraglia E, Conte I, Stansfield I, et al. Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg Med Chem Lett 2002; 12: 705-8.
66. Colarusso S, Koch U, Gerlach B, Steinkuhler C, De Francesco R, Altamura S, et al. Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling. J Med Chem 2003; 46: 345-8.
67. Di Marco S, Rizzi M, Volpari C, Walsh MA, Narjes F, Colarusso S, et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000; 275: 7152-7.
68. Narjes F, Brunetti M, Colarusso S, Gerlach B, Koch U, Biasiol G, et al. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry 2000; 39: 1849-61.
69. Narjes F, Koehler KF, Koch U, Gerlach B, Colarusso S, Steinkuhler C, et al. A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg Mod Chem Lett 2002; 12: 701-4.
70. Narjes F, Koch U, Steinkuhler C. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antiviral agents? Expert Opin Investig Drugs 2003, 12: 153-63.
71. Steinkuhler C, Koch U, Narjes F. Matassa VG. Hepatitis C virus protease inhibitors: current progress and future challenges. Curr Med Chem 2001; 8: 919-32.
72. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77: 3669-79.
73. Clough J. A 'C change for hepatitis treatment. Drug Discov Today 2002; 7: 335-6.
74. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-14.
75. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998: 282; 103-7.
76. Wu Z, Yao N, Le HV, Weber PC. Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein. Trends Biochem Sci 1998; 23: 92-4.
77. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 4665-75.
78. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci U S A 2001; 98: 13931-5.
79. Whitney M, Ståck JH, Darke PL, Zheng W, Terzo J, Inglese J, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. J Biomol Screen 2002; 7: 149-54.
80. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med 2004; 10: 368-73.
81. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, et al. A previously undescribed coronavirus associated with respiratory disease in human. Proc Natl Acad Sci U S A 2004; 101: 6212-6.
82. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded protainases and proteolytic processing in the Nidovirales. J Gen Virol 2000; 81: 853-79.
83. Hegyi A, Friebe A, Gorbalenya AE, Ziebuhr J. Mutational analysis of the active centre of coronavirus 3C-like proteases. J Gen Virol 2002; 83: 581-93.
84. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 2002; 21: 3213-24.
85. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A 2003; 100: 13190-5.
86. Matthews DA, Smith WW, Ferro RA, Condon B, Budahazi G, Sisson W, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994; 77: 761-71.
87. Chou KC, Wei DQ, Zhong WZ. Binding mechanism of coronavirus. main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 2003; 308: 148-51.
88. pro. Biochemistry 2004; 43: 4906-12.
89. Kuo CJ, Chi YH, Hsu JT, Liang PH. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem Biophys Res Common 2004; 318: 862-7.
90. Hsu J TA, Kuo CJ, Hsieh HP, Wang YC, Huang KK, Lin C PC, et al. Evaluation of Metal-Conjugated Compounds as Inhibitors of 3CL Protease of SARS-CoV. FEBS Lett 2004; 574: 116-20.
91. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YS, et al. Small molecules targeting severe acute respiratory syndrome human coranavirus. Proc Natl Acad Sci U S A 2004; 101: 10012-7.
92. Chen P, Tsuge H, Almassy RJ, Gribskov CL, Katoh S, Vanderpool DL, et al. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 1996; 86: 835-43.
93. Qiu X, Janson CA, Culp JS, Richardson SB, Debouck C, Smith WW, et al. Crystal structure of varicella-zoster virus protease. Proc Natl Acad Sci U S A 1997; 94: 2874-9.
94. Reiling KK, Pray TR, Craik CS, Stroud RM. Functional consequences of the Kaposi's sarcoma-associated herpesvirus protease structure: regulation of activity and dimerization by conserved structural elements. Biochemistry 2000; 39: 12796-803.
95. Shieh HS, Kurumbail RG, Stevens AM, Stegeman RA, Sturman EJ, Pak JY, et al. Three-dimensional structure of human cytomegalovirus protease. Nature 1996; 383: 279-82.
96. Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagace L. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 1996; 383: 272-5.
97. Kan CC. Impact of recombinant DNA technology and protein engineering on structure-based drug design: case studies of HIV-1 and HCMV proteases. Curr Top Med Chem 2002; 2: 247-69.
98. Griffin DE. A review of alphavirus replication in neurons. Neurosci Biobehav Rev 1998; 22: 721-3.
99. Ehrengruber MU. Alphaviral gene transfer in neurobiology. Brain Res Bull 2002; 59: 13-22.
100. Shirako Y, Strauss JH. Regulation of Sindbis virus RNA replication: uncleaved P123 and nsP4 function in minus-strand RNA synthesis, whereas cleaved products from P123 are required for efficient plus-strand RNA synthesis. J Virol 1994; 68: 1874-85.
101. Takkinen K. Complete nucleotide sequence of the nonstructural protein genes of Semliki Forest virus. Nucleic Acids Res 1986; 14: 5667-82.
102. Strauss EG, Rice CM, Strauss JH. Complete nucleotide sequence of the genomic RNA of Sindbis virus. Virology 1984; 133: 92-110.
103. Vasiljeva L, Valmu L, Kaariainen L, Merits A. Site-specific protease activity of the carboxyl-terminal domain of Semliki Forest virus replicase protein nsP2. J Biol Chem 2001; 276: 30786-93.
104. Strauss EG, De Groot RJ, Levinson R, Strauss JH. Identification of the active site residues in the nsP2 proteinase of Sindbis virus. Virology 1992; 191: 932-40.
105. Hara K, Shiota M, Kido H, Ohtsu Y, Kashiwagi T, Iwahashi J, et al. Influenza virus RNA polymerase PA subunit is a novel serine protease with Ser624 at the active site. Genes Cells 2001; 6: 87-97.
106. Toyoda T, Hara K, Imamura Y. Ser624 of the PA subunit of influenza A virus is not essential for viral growth in cells and mice, but required for the maximal viral growth. Arch Virol 2003; 148: 1687-96.
107. Hara K, Shiota M, Kido H, Watanabe K, Nagata K, Toyoda T. Inhibition of the protease activity of influenza virus RNA polymerase PA subunit by viral matrix protein. Microbiol Immunol 2003; 47: 521-6.
108. Barbato G, Cicero DO, Cordier F, Narjes F, Gerlach B, Sambucini S, et al. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain. EMBO J 2000; 19: 1195-206.
109. Herold J, Gorbalenya AE, Thiel V, Schelle B, Siddell SG. Proteolytic processing at the amino terminus of human coronavirus 229E gene 1-encoded polyproteins: identification of a papain-like proteinase and its substrate. J Virol 1998; 72: 910-8.
110. Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO J 1999; 18: 5463-75.
111. Cheah KC, Leong LE, Porter AG. Site-directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. J Biol Chem 1990; 265: 7180-7.
112. Yu SF, Lloyd RE. Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology 1991; 182: 615-25.
113. Kean KM, Howell MT, Grunert S, Girard M, Jackson RJ. Substitution mutations at the putative catalytic triad. of the poliovirus 3C protease have differential effects an cleavage at different sites. Virology 1993; 194: 360-4.
114. Kuo RL, Kung SH, Hsu YY, Liu WT. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol 2002; 83: 1367-76.
115. Li ML, Hsu TA, Chen TC, Chang SC, Lee JC, Chen CC, et al. The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology 2002; 293: 386-95.
116. Piccone ME, Zellner M, Kumosinski TF, Mason PW, Grubman MJ. Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus. J Virology 1995; 69: 4950-6.
117. Grubman MJ, Zellner M, Bablanian G, Mason PW, Piccone ME. Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology 1995; 213: 581-9.
118. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337: 615-20.
119. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10(3): 315-36.
120. Martinez-Salas E, Fernandez-Miragall O. Picornavirus IRES: structure function relationship. Curr Pharm Des 2004, 10(30): 3757-67.
121. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 2004; 10(32): 4055-64.